Haemonetics (NYSE:HAE – Get Free Report) and Butterfly Network (NYSE:BFLY – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Institutional & Insider Ownership
99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 37.9% of Butterfly Network shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by insiders. Comparatively, 22.0% of Butterfly Network shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Haemonetics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Butterfly Network has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Haemonetics | 0 | 3 | 7 | 1 | 2.82 |
| Butterfly Network | 1 | 1 | 5 | 1 | 2.75 |
Haemonetics currently has a consensus target price of $126.38, suggesting a potential upside of 4.78%. Butterfly Network has a consensus target price of $8.75, suggesting a potential upside of 27.46%. Given Butterfly Network’s higher possible upside, analysts clearly believe Butterfly Network is more favorable than Haemonetics.
Profitability
This table compares Haemonetics and Butterfly Network’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Haemonetics | 7.52% | 27.42% | 9.77% |
| Butterfly Network | -43.56% | -21.60% | -14.25% |
Valuation & Earnings
This table compares Haemonetics and Butterfly Network”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Haemonetics | $1.33 billion | 4.12 | $97.31 million | $2.23 | 54.09 |
| Butterfly Network | $97.61 million | 18.81 | -$77.06 million | ($0.21) | -32.69 |
Haemonetics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
Summary
Haemonetics beats Butterfly Network on 10 of the 14 factors compared between the two stocks.
About Haemonetics
Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.
About Butterfly Network
Butterfly Network develops portable ultrasound technology for healthcare professionals. Its handheld devices use the company’s semiconductor-based Ultrasound-on-Chip technology to produce ultrasound images and connect with compatible mobile devices, offering an alternative to larger, cart-based systems. The company’s products include the Butterfly iQ line of handheld ultrasound devices, along with software and cloud-based tools for viewing, managing and sharing medical images. Its offerings are designed for use across a range of clinical settings and applications.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
